Cancer Immunotherapy Biomarker
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 28 February 2025
Special Issue Editors
Interests: cytopathology; immunohistochemistry; cancer; systematic review and meta-analysis; medical education
Special Issues, Collections and Topics in MDPI journals
Interests: pathology; cancer pathology; colorectal cancer; lung cancer; pancreatic cancer; breast cancer; inflammation; infectious agents; cell cycle; metabolism
Special Issues, Collections and Topics in MDPI journals
Interests: cancer genomics; precision medicine; data science in genomics; next-generation sequencing; translational oncology; tumor immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy has been associated with durable response and longer survival of cancer patients, yet a fraction of them are eligible. Several cancer immunotherapy types exist, such as monoclonal antibodies, cytokines, CAR T-cell therapy, and immune checkpoint inhibitors (ICIs). To select patients for therapy with ICIs, practitioners evaluate well-established biomarkers, including the programmed cell death ligand-1 (PD-L1), mismatch repair/microsatellite instability (MMR/MSI), and tumor mutational burden (TMB). Despite the breakthroughs in this field, additional biomarkers would be needed to increase the eligibility for immunotherapy of patients with cancer and improve their prognosis in clinical practice. This Special Issue welcomes original studies, reviews, and short communications, discussing novel cancer biomarkers related to immunotherapy. Large-scale studies are particularly welcome, focusing on basic and/or translational research. Potential topics may include the following:
- Biomarkers assessed with immunohistochemistry, immunofluorescence, or high-throughput sequencing techniques in cancer tissue or cytology samples;
- Biomarkers assessed in liquid biopsy materials;
- Biomarkers predicting response or resistance to immunotherapy;
- Impact of intratumoral heterogeneity on immunotherapy responses;
- Use of “multi-omics data” and bioinformatics tools or artificial intelligence to predict response or resistance to immunotherapy;
- Spatial profiling to investigate the tumor microenvironment in cancer;
- Systematic reviews and meta-analyses focusing on well-established or emerging cancer immunotherapy biomarkers.
Dr. Ilias P. Nikas
Dr. Ioannis Pateras
Dr. Apostolos Zaravinos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor microenvironment
- tumor immunology
- cancer biomarkers
- immunotherapy
- immunohistochemistry
- pathology
- personalized medicine
- omics technologies
- prognosis and therapy
- bioinformatics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
